LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
DexCom
DXCM
Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
Constellation Brands
STZ
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | 20.74%9.2B | 0.53%7.14B | -9.00%8.46B | -27.78%8.69B | -27.78%8.69B | -44.12%7.62B | -47.96%7.11B | -35.66%9.3B | -27.47%12.03B | -27.47%12.03B |
-Cash and cash equivalents | 22.01%9.19B | 0.68%7.06B | -9.03%8.38B | -27.22%8.6B | -27.22%8.6B | -44.34%7.53B | -48.28%7.01B | -36.28%9.21B | -28.54%11.82B | -28.54%11.82B |
-Money market investments | -87.85%10.65M | -10.85%86.68M | -5.79%84.65M | -59.24%84.65M | -59.24%84.65M | -15.56%87.65M | -7.89%97.23M | --89.85M | 394.73%207.68M | 394.73%207.68M |
Net loan | 9.00%19.79B | 12.72%19.74B | 10.92%19.14B | 9.75%18.58B | 9.75%18.58B | 8.62%18.16B | 6.16%17.51B | 5.88%17.25B | 5.22%16.93B | 5.22%16.93B |
-Gross loan | 9.00%20.05B | 12.68%20B | 10.88%19.39B | 9.73%18.82B | 9.73%18.82B | 8.55%18.4B | 6.04%17.75B | 5.70%17.49B | 5.01%17.15B | 5.01%17.15B |
-Allowance for loans and lease losses | 8.63%263.13M | 9.71%256.31M | 8.11%250.3M | 8.07%246M | 8.07%246M | 3.38%242.24M | -2.51%233.62M | -6.21%231.51M | -8.46%227.62M | -8.46%227.62M |
Securities and investments | -4.31%18.92B | -10.28%18.82B | -13.35%18.82B | -3.26%20.23B | -3.26%20.23B | 0.90%19.77B | 11.84%20.97B | 21.49%21.72B | 33.20%20.91B | 33.20%20.91B |
-Trading securities | 10.27%32.35M | -1.02%32.19M | 37.97%39.65M | 13.09%31.72M | 13.09%31.72M | 17.33%29.34M | 31.75%32.52M | -2.65%28.74M | 11.46%28.05M | 11.46%28.05M |
-Held to maturity securities | -1.61%3.57B | -2.85%3.59B | -2.99%3.6B | 37.15%3.62B | 37.15%3.62B | 66.88%3.63B | 89.64%3.69B | 122.86%3.71B | 50.88%2.64B | 50.88%2.64B |
-Short term investments | -4.95%15.32B | -11.89%15.2B | -15.57%15.18B | -9.13%16.58B | -9.13%16.58B | -7.37%16.12B | 2.79%17.25B | 11.10%17.98B | 31.02%18.24B | 31.02%18.24B |
Bank owned life insurance | ---- | ---- | ---- | ---- | ---- | ---- | 0.40%190.58M | 0.60%190.6M | ---- | ---- |
Net PPE | 5.37%1.23B | 5.79%1.22B | 7.10%1.21B | 7.92%1.19B | 7.92%1.19B | 9.15%1.17B | 10.30%1.15B | 8.05%1.13B | 4.99%1.1B | 4.99%1.1B |
-Gross PPE | ---- | ---- | ---- | 8.03%1.58B | 8.03%1.58B | ---- | ---- | ---- | 5.30%1.47B | 5.30%1.47B |
-Accumulated depreciation | ---- | ---- | ---- | -8.34%-394.03M | -8.34%-394.03M | ---- | ---- | ---- | -6.26%-363.68M | -6.26%-363.68M |
Goodwill and other intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | -0.06%655.16M | -0.07%655.24M | ---- | ---- |
-Goodwill | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%654.95M | 0.00%654.95M | ---- | ---- |
-Other intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | -64.69%208K | -59.72%290K | ---- | ---- |
Other assets | -8.08%1.87B | 91.34%1.92B | 88.75%1.87B | 12.29%2.16B | 12.29%2.16B | 87.38%2.03B | 1.92%1B | 28.31%990.8M | 214.03%1.92B | 214.03%1.92B |
Total assets | 4.64%51.01B | 0.51%48.84B | -3.40%49.51B | -3.87%50.85B | -3.87%50.85B | -7.93%48.75B | -6.16%48.6B | -0.10%51.25B | 3.96%52.89B | 3.96%52.89B |
Liabilities | ||||||||||
Total deposits | 1.78%41.72B | -0.94%40.32B | -3.27%40.81B | -4.63%41.92B | -4.63%41.92B | -11.96%40.99B | -10.75%40.7B | -5.06%42.18B | 2.95%43.95B | 2.95%43.95B |
Federal funds purchased and securities sold under agreement to repurchase | 7.69%4.04B | 6.01%3.8B | -7.23%3.98B | -12.12%4.14B | -12.12%4.14B | 77.73%3.75B | 109.81%3.58B | 128.72%4.29B | 70.32%4.71B | 70.32%4.71B |
Long term debt and capital lease obligation | 0.10%222.78M | 0.10%222.72M | 0.10%222.67M | 0.10%222.62M | 0.10%222.62M | 0.10%222.56M | 0.10%222.51M | 0.10%222.46M | 0.10%222.4M | 0.10%222.4M |
-Long term debt | 0.10%222.78M | 0.10%222.72M | 0.10%222.67M | 0.10%222.62M | 0.10%222.62M | 0.10%222.56M | 0.10%222.51M | 0.10%222.46M | 0.10%222.4M | 0.10%222.4M |
Other liabilities | 13.87%893.08M | 18.96%837.16M | -20.69%853.68M | -2.57%844.02M | -2.57%844.02M | -36.83%784.28M | -22.32%703.72M | 8.86%1.08B | 14.84%866.26M | 14.84%866.26M |
Total liabilities | 2.46%46.87B | -0.07%45.18B | -4.00%45.87B | -5.28%47.13B | -5.28%47.13B | -8.75%45.75B | -6.66%45.21B | 0.54%47.78B | 7.14%49.76B | 7.14%49.76B |
Shareholders'equity | ||||||||||
Share capital | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M | 0.00%146.1M |
-common stock | 0.00%644K | 0.00%644K | 0.00%644K | 0.16%644K | 0.16%644K | 0.31%644K | 0.31%644K | 0.31%644K | 0.16%643K | 0.16%643K |
-Preferred stock | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M | 0.00%145.45M |
Paid-in capital | 2.10%1.07B | 2.24%1.06B | 2.28%1.06B | 2.53%1.06B | 2.53%1.06B | 2.48%1.04B | 2.49%1.04B | 2.36%1.04B | 1.96%1.03B | 1.96%1.03B |
Retained earnings | 7.24%3.89B | 7.85%3.81B | 8.68%3.73B | 10.52%3.66B | 10.52%3.66B | 14.05%3.63B | 15.06%3.53B | 14.20%3.43B | 11.93%3.31B | 11.93%3.31B |
Less: Treasury stock | 32.71%50.67M | 63.00%45.03M | 1,499.55%17.74M | --23.93M | --23.93M | 1,062.31%38.18M | 163.75%27.62M | -91.26%1.11M | --0 | --0 |
Gains losses not affecting retained earnings | 48.54%-915.43M | -0.33%-1.31B | -11.75%-1.28B | 16.99%-1.12B | 16.99%-1.12B | -16.34%-1.78B | -49.28%-1.31B | -207.20%-1.14B | -488.20%-1.35B | -488.20%-1.35B |
Total stockholders'equity | 37.85%4.14B | 8.24%3.67B | 4.91%3.64B | 18.46%3.72B | 18.46%3.72B | 6.66%3B | 1.19%3.39B | -8.17%3.47B | -29.33%3.14B | -29.33%3.14B |
Total equity | 37.85%4.14B | 8.24%3.67B | 4.91%3.64B | 18.46%3.72B | 18.46%3.72B | 6.66%3B | 1.19%3.39B | -8.17%3.47B | -29.33%3.14B | -29.33%3.14B |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |